Results 21 to 30 of about 8,771 (219)

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation

Качественная клиническая практика, 2020
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods.
A. M. Lila, S. K. Zyryanov, I. N. Dyakov
doaj   +1 more source

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Arthritis Research & Therapy, 2021
Background The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic ...
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein, Yoshiya Tanaka   +9 more
doaj   +1 more source

In vitro effect of upadacitinib and tofacitinib on peripheral blood leukocytes from early and established arthritis patients [PDF]

, 2023
A artrite reumatóide (AR) é uma doença inflamatória crónica, sistémica, imuno-mediada que afeta principalmente as articulações. Quando não tratada, a AR pode levar à destruição óssea e da cartilagem.
Bento, Catarina Alexandra Morais Fernandes da Costa
core  

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib [PDF]

, 2023
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis.
Cantisani C., Caviglia M., Chello C., Cusano G., Del Duca E., Grieco T., Ianiro G., Pellacani G., Sernicola A., Sini N., Taliano A.   +10 more
core   +1 more source

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from SELECT-COMPARE over 5 years.Methods Patients with rheumatoid arthritis and inadequate response to methotrexate were randomised to receive upadacitinib 15 mg once daily ...
Roy Fleischmann, Patrick Durez, Eduardo Mysler, Louis Bessette, Yihan Li, Nasser Khan, Charles G Peterfy, Jerzy Swierkot, Xianwei Bu, Sara K Penn   +9 more
doaj   +1 more source

Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients

RMD Open
Objectives To evaluate the effectiveness and safety of upadacitinib in treatment-refractory inflammatory myositis.Methods Patients with refractory inflammatory myositis treated with upadacitinib from a single urban centre in Vancouver, British Columbia ...
Kun Huang, Jan Dutz, Madelaine Beckett
doaj   +1 more source

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +1 more source

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Arthritis Research & Therapy
Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the ...
Ronald van Vollenhoven, Vibeke Strand, Tsutomu Takeuchi, Nilmo Chávez, Pablo Mannucci Walter, Atul Singhal, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, Sara K. Penn, Heidi S. Camp, Jacob Aelion   +12 more
doaj   +1 more source

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials [PDF]

, 2022
Introduction: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior ...
Azevedo V. F., Blanco R., Burmester G. R., Goupille P., Lertratanakul A., Lesser E., Lippe R., Liu J., Mccaskill R. M., Nash P., Rubbert-Roth A., Ruderman E. M., Salvarani C., Winthrop K.   +13 more
core   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, EarlyView.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source